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Extracellular palladium-catalysed dealkylation of
5-ﬂuoro-1-propargyl-uracil as a bioorthogonally
activated prodrug approach
Jason T. Weiss1, John C. Dawson1, Kenneth G. Macleod1, Witold Rybski1,2, Craig Fraser1,
Carmen Torres-Sa´nchez3, E. Elizabeth Patton1,2, Mark Bradley4, Neil O. Carragher1 & Asier Unciti-Broceta1
A bioorthogonal organometallic reaction is a biocompatible transformation undergone by a
synthetic material exclusively through the mediation of a non-biotic metal source; a selective
process used to label biomolecules and activate probes in biological environs. Here we report
the in vitro bioorthogonal generation of 5-ﬂuorouracil from a biologically inert precursor by
heterogeneous Pd0 catalysis. Although independently harmless, combined treatment of
5-ﬂuoro-1-propargyl-uracil and Pd0-functionalized resins exhibits comparable antiproliferative
properties to the unmodiﬁed drug in colorectal and pancreatic cancer cells. Live-cell imaging
and immunoassay studies demonstrate that the cytotoxic activity of the prodrug/Pd0-resin
combination is due to the in situ generation of 5-ﬂuorouracil. Pd0-resins can be carefully
implanted in the yolk sac of zebraﬁsh embryos and display excellent biocompatibility and
local catalytic activity. The in vitro efﬁcacy shown by this masking/activation strategy
underlines its potential to develop a bioorthogonally activated prodrug approach and supports
further in vivo investigations.
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B
ertozzi’s landmark works in the early 2000s (refs 1,2)
demonstrated that artiﬁcial chemistry and biological
chemistry can take place within the same physical space,
yet do not interfere with each other. Through the development of
labelling strategies based on the chemospeciﬁc conjugation of two
biologically-inert reactive partners, this revolutionary chemical
paradigm—so-called bioorthogonal chemistry—has enabled the
non-intrusive real-time study of a wide range of biomolecules in
their native environs3,4. Because of the exclusive nature of the
bioorthogonal concept, the range of chemical reactions that
meets its requirements has been limited in practice to the
Staudinger ligation1 and cycloadditions between spring-loaded
reactive partners (metal-free click chemistry2–4). Nevertheless, the
bioorthogonal concept may integrate additional bio-independent
chemical processes that are promoted by abiotic activators such as
biocompatible electromagnetic radiations5–7 and non-biological
transition metals8,9.
Although the application of transition metals in medicine have
been investigated for many centuries, its use to mediate
chemoselective transformations in cells—for example, bioorthogo-
nal organometallic (BOOM) reactions8—is a recent addition
to the chemical biology ﬁeld8–14. In 2006, Streu and Meggers10
described the ﬁrst application of a ruthenium catalyst
to carry out Alloc deprotection of a caged ﬂuorophore inside
human cells. The aim to minimize the inherent toxicity of the
catalyst motivated the Bradley group to investigate heterogeneous
catalysis to mediate palladium chemistry inside cells. Pd0-
functionalized microspheres operated as a dual catalytic/cell
delivery system able to enter cells in vitro and catalyse
allylcarbamate cleavage and Suzuki-Miyaura cross-coupling in the
cytoplasm without cytotoxicity9,11. Notable examples of palladium-
based applications in cell culture includes copper-free Sonogashira
coupling of an alkyne-encoded cytoplasmic ubiquitin protein12,
extracellular Suzuki reaction to label Escherichia coli cell surface
components13 and the detection of intracellular CO based on the
reactivity of a cyclopalladated probe towards carbonylation14.
Owing to its biological inertness, metallic Pd0 shows the safest
toxicity proﬁle among all palladium species15 and is frequently
used in metal alloys for dental restoration16. Based on the unique
catalytic properties and biocompatibility of this metal, we
hypothesized that extracellular heterogeneous catalysis mediated
by a palladium-functionalized implant could enable the chemo-
speciﬁc conversion of a systemically administered prodrug into its
active form in a spatially controlled manner. As opposed to
biolabile prodrugs, whose activation process relies on metabolic
pathways17, an efﬁcient palladium-activated prodrug therapy
would be entirely dependent on the distinct catalytic properties of
this transition metal and therefore the prodrug would remain
intact in the absence of a palladium source. By intratumoural
implantation of a metal-functionalized device, palladium-labile
prodrugs would be exclusively activated within the cancerous
tissue. Locoregional generation of cytotoxic agents would enable
increasing dosing while reducing adverse side effects in distant
tissues and organs, an optimal strategy to treat advanced tumours
that cannot be resected by surgery. Notably, this spatially targeted
approach would serve to expand the therapeutic window
and scope of potent cytotoxic drugs such as 5-ﬂuorouracil
(5FU), which has a long history in oncology practice but a clinical
activity limited by its safety proﬁle18.
5FU is converted intracellularly into cytotoxic nucleotidic
metabolites via functionalization on its N1 position. Its active
metabolites either inhibit directly thymidylate synthase or
become incorporated into RNA and DNA molecules to disrupt
normal cell functions (Fig. 1)19. Based on this mode of action,
modiﬁcation of the N1 position of 5FU with biochemically stable
groups would hinder its intracellular activation and result in a
signiﬁcant loss of cytotoxic activity. Here we report the
introduction of allyl, propargyl and benzyl moieties at the N1
position of 5FU as a means to minimize prodrug’s susceptibility
to cleavage by hydrolytic enzymes, while, at the same time,
rendering them potentially sensitive to palladium catalysis. These
alkyl functional groups have been widely used in organic
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Figure 1 | Bioorthogonally activated prodrug strategy and toxigenic mode of action. Chemical masking of the N1 position of 5-ﬂuorouracil (5FU) with
a biochemically inert palladium-sensitive group would impede 5FU intracellular activation and, consequently, prevent its pharmacological activity.
Such a prodrug will be selectively converted into 5FU by the catalysis of Pd0, for instance, in the affected area, organ or tissue where a Pd0-functionalized
device has been surgically implanted, thus inducing a local treatment of the disease and reducing side effects of drug in distant tissues and organs. dTMP,
thymidine monophosphate; dUMP, deoxyuridine monophosphate.
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synthesis as OH protection strategies20 and, importantly, recent
studies have shown the sensitivity of allyl and propargyl phenolic
ethers to oxidative cleavage by palladium species in biocompatible
conditions21–23. Although palladium-mediated N-dealkylations
typically require temperatures incompatible with cell survival
(480 C)24–26, we hypothesized that the particular features
of the 5FU heterocyclic system (relatively low pKa values
because of the charge delocalization of 5FU aromatic conjugate
bases27, Supplementary Fig. 1a) could promote its properties as a
leaving group relative to more basic amino groups.
To activate prodrugs in the extracellular space, we investigate
the application of a robust heterogeneous catalytic system based
on Pd0-functionalized polyethylene glycol (PEG)-polystyrene
resins28 (Pd0-resins) that are larger than human cells (150 mm
in diameter). As previously reported9,11, Pd0 nanoparticles
display high catalytic activity, can be readily generated and
trapped in an amino-functionalized polymer matrix, and are safe
for biological applications. Our results show that alkylation of the
N1 position of 5FU suppresses the drug’s cytotoxic properties and
exhibits full stability in cell culture. Remarkably, the propargyl
derivative (5-ﬂuoro-1-propargyl-uracil (Pro-5FU)) displays high
sensitivity to Pd0-mediated heterogeneous catalysis, thus allowing
the bioorthogonal generation of 5FU under biocompatible
conditions (37 C, isotonic media and physiologic pH).
Although independently harmless, combined treatment of Pro-
5FU and Pd0-resins exhibits equivalent antiproliferative
properties to unmodiﬁed 5FU in colorectal and pancreatic
cancer cells, underlining the in vitro efﬁcacy of this
unprecedented masking/activation strategy.
Results
Preparation of Pd0-resins and 5FU prodrugs. Pd0-resins
(Fig. 2a,b) were prepared from NovaSyn TG amino resin HL
using the procedure developed in the Bradley group28 with minor
modiﬁcations. Transmission electron microscope images showed
dark nanoparticles (5 nm) regularly distributed across the resins
(Fig. 2b), whereas the powder X-ray diffraction spectra presented
the distinctive pattern of the face-centred cubic lattice of Pd0
(Supplementary Fig. 1b). Pd0-resins were visibly differentiated
from non-functionalized resins (naked resins) because of the dark
colour of the former (Supplementary Fig. 1c). Palladium content
was determined to be 2.83% (w/w) by inductively coupled
plasma-optical emission spectrometry.
1-Allyl-5FU (All-5FU), Pro-5FU and 1-benzyl-5FU (Bn-5FU;
Fig. 2c) were synthesized in a single step by reaction of 5FU with
the corresponding alkyl bromide in the presence of 1,8-
diazabicyclo[5.4.0]undec-7-ene. N-propargyl-2-pyridone (1a)
and N-propargyl-4-pyridone (1b) were synthesized following
the same procedure (Supplementary Methods).
Cell-free Pd0-mediated prodrug-into-drug conversion. To
recreate a biocompatible scenario, reactions were carried out at
37 C in an isotonic solution with a physiologic pH. Prodrugs
(100 mM) and Pd0-resins (1mgml 1, [Pd0]¼ 266 mM) were
dispersed in PBS, incubated for 6–48 h and analysed by high-
performance liquid chromatography (HPLC). Figure 2d shows
Pro-5FU completely disappeared from the crude mixture after
24 h, with 5FU being the major reaction product. In accordance
with previous observations26, mass spectrometry analysis of the
reaction crude indicated the formation of nontoxic 1-
hydroxyacetone—a natural lipid metabolite also known as
acetol29—as a byproduct from the oxidative cleavage of the
propargyl group (Supplementary Fig. 2a,b). In contrast,
conversion analysis of All-5FU and Bn-5FU did not show
substantial levels of 5FU after 48 h (Supplementary Fig. 3a).
N-Depropargylation of Pro-5FU using sub-stoichiometric
amounts of Pd0 conﬁrmed the catalytic nature of the reaction,
albeit 72 h were required to achieve completion (Supplementary
Fig. 3b). To determine whether Pro-5FU dealkylation is mediated
by heterogeneous catalysis, Pd0-resins were incubated in PBS at
37 C for 24 h, micro-ﬁltered to eliminate solid contents and
Pro-5FU added to the solid-free solution for additional 24h
incubation. HPLC analysis detected unreacted Pro-5FU as major
mixture component and relatively small quantities of 5FU
(Supplementary Fig. 3c), indicating that Pd0 is in part released
from the resins into the solution, although this amount contributes
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Figure 2 | Pd0-mediated prodrug-into-drug conversion assays in biocompatible environment. (a) Scanning electron microscope image of Pd0-resins at
approximately 200 magniﬁcation. Scale bar, 50mm. (b) Transmission electron microscope image of a Pd0-resin cross-section at approximately 190,000
magniﬁcation. Scale bar, 50nm. (c) Pd0-mediated dealkylation of 5-ﬂuorouracil (5FU) prodrugs under biocompatible conditions (37 C, isotonic media and
physiologic pH). (d) Representative HPLC traces of Pd0-mediated conversion of Pro-5FU into 5FU. Reaction crudes were analysed using an ultraviolet detector
(280nm) at t¼0h, t¼ 6h and t¼ 24h. Conversion studies were performed in triplicate. All-5FU, 1-allyl-5FU; Bn-5FU, 1-benzyl-5FU; Pro-5FU, 5-ﬂuoro-1-
propargyl-uracil.
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minimally to the reaction catalysis. Treatment of two additional N-
propargylated heterocycles, N-propargyl-2-pyridone (1a) and N-
propargyl-4-pyridone (1b), under the same conditions afforded the
dealkylated derivatives in 24 h (Supplementary Fig. 3d).
Pro-5FU bioorthogonality. Based on the primary malignancies
against which 5FU is currently prescribed18,19, colorectal HCT116
and pancreatic BxPC-3 cancer cell lines were chosen as models for
antiproliferative and mechanism-of-action studies. To evaluate the
efﬁcacy of the masking strategy in suppressing 5FU cytotoxic
properties, dose response studies were carried out with unmodiﬁed
drug and Pro-5FU (0.01mM to 1mM). Cell viability was
determined at day 5 using PrestoBlue reagent and analysed by
spectroﬂuorometry to calculate EC50 (5FU) values of 2 and
0.14mM for HCT116 and BxPC-3 cells, respectively
(Supplementary Fig. 4a,b). Notably, Pro-5FU displayed no
cytotoxicity at any concentration used (EC50 [Pro-5FU]/EC50
[5FU]4500), proving the effectiveness of the deactivation strategy.
To test whether Pro-5FU could be biotransformed
into 5FU in cells with higher metabolic capacity, cell viability
assays were carried out in liver HepG2 cells30. As shown in
Supplementary Fig. 4c, although 5FU was signiﬁcantly cytotoxic at
low micromolar concentration (EC50¼ 1.4mM), Pro-5FU did not
exhibit a toxic effect (EC50 41mM), illustrating the high
biochemical stability of the propargyl group to enzymatic cleavage.
Because of the close structural similarities between Pro-5FU
and 5FU, it was considered that the prodrug could function as a
competitive inhibitor of the enzymatic routes followed by 5FU to
generate its cytotoxic metabolites. This potential drawback of the
prodrug strategy was ruled out by incubating 5FU with increasing
concentrations of Pro-5FU up to a prodrug/drug ratio of 100:1,
which exhibited no antagonistic effect (Supplementary Fig. 5a,b).
In addition, dose response studies of 1-hydroxyacetone (main
reaction byproduct) with HCT116 and BxPC-3 cancer cell lines
showed no effect in cell viability (Supplementary Fig. 5c,d).
Antiproliferative effect of Pro-5FU/Pd0-resin combination.
After assessing the catalyst concentration range tolerated by cells
and optimal for catalysis (Supplementary Fig. 6), 1mgml 1 (for
HCT116) and 0.66mgml 1 (for BxPC-3) of Pd0-resins were
used for the biological assays. Preliminary cell screening of pal-
ladium-mediated generation of 5FU from the three prodrugs
conﬁrmed that Pro-5FU/Pd0-resin combination was effective in
producing a strong toxigenic effect (Supplementary Fig. 7a,b).
Hence, a range of concentrations of Pro-5FU and Pd0-resins was
incubated independently (negative controls) and in combination
(BOOM conversion assay) to study cell proliferation in com-
parison to unmodiﬁed 5FU (positive control). As observed in
Fig. 3a,b, the toxigenic effect generated by the prodrug/catalyst
combination was comparable to 5FU cytotoxicity, exhibiting
similar EC50 values (Supplementary Fig. 7c,d). Independently
incubated, neither the prodrug nor the palladium source exhib-
ited antiproliferative activity.
Cytotoxic mode of action of Pro-5FU/Pd0-resin combination.
To study the phenotypic effect of the prodrug/catalyst system
compared with 5FU, cell proliferation was monitored in real-time
using an IncuCyte ZOOM microscope, which allows quantiﬁca-
tion of cell conﬂuence as a function of time by image-based
analysis. As shown in Fig. 3c,d, negative controls exhibited a
standard growth curve, whereas the proliferation of cells treated
with 5FU rapidly decreased after a few hours. Growth curves of
HCT116 cells incubated with the Pd0-resin/Pro-5FU combination
showed two distinct phases: a regular increment for 24 h followed
by a drastic fall to reach cytotoxic levels comparable to 5FU at day
5. In the case of BxPC-3 cells, population curves of cells incubated
with either 5FU or the Pd0-resin/Pro-5FU combination showed
similar bell-shaped growth curves. As observed in Fig. 3e,f and
Supplementary Movies 1 and 2, treatment-induced changes in cell
morphology indicate analogous antiproliferative/cell death
induction between 5FU and the prodrug/catalyst system.
To study these phenotypic responses at the molecular level,
total expression and post-translational modiﬁcations of cancer
relevant pathways were quantiﬁed using Zeptosens Reverse
Phase Protein Microarray analysis31. Supplementary Fig. 8a
shows that total and phosphorylated p53 (Ser15) were signi-
ﬁcantly upregulated in HCT116 cells at 24 h following exposure
to Pro-5FU/Pd0-resin combination, which correlates with the
response observed under 5FU treatment and the DNA damage
response mechanism expected from this drug32. In contrast, no
induction was observed in cells treated with either Pro-5FU or
Pd0-resin on their own. These observations were corroborated by
western blotting (Supplementary Fig. 9).
Pd0-Resin biocompatibility and catalytic activity in zebraﬁsh.
The biocompatibility of the palladium-functionalized device
in vivo was investigated by carefully introducing a single
Pd0-resin in the yolk sac of zebraﬁsh embryos 24 h after fertili-
zation and monitoring their early development by phase contrast
microscopy. As shown in Fig. 4a, zebraﬁsh embryos containing a
Pd0-resin (indicated with a red arrow) developed normally into
the larval stage with no signs of toxicity or alteration of
phenotype.
To study the catalytic functionality of the Pd0-resins in the
zebraﬁsh yolk, palladium-sensitive pro-ﬂuorophore 3 (Fig. 4b) was
prepared and incubated with zebraﬁsh embryos containing either a
non-functionalized resin (naked resin) or a Pd0-resin for 24h.
N,N0-bis(propargyloxycarbonyl)-protected rhodamine 110 (3) was
synthesized from rhodamine 110 chloride by reaction with
propargyl chloroformate and triethylamine in dry dimethylforma-
mide (DMF). The enhanced lipophilic properties of non-
ﬂuorescent probe 3 facilitated its diffusion across biological
barriers. On the contrary, highly ﬂuorescent rhodamine 110
generated upon propargylcarbamate cleavage was trapped in the
physiological compartment where it was produced because of its
high hydrophilicity, thus enabling the imaging of localized
palladium-mediated catalysis8,10,11. As shown in Fig. 4c, a strong
ﬂuorescent signal was clearly observed from the area surrounding
the Pd0-resin in the yolk sac (lower panel), conﬁrming that the
palladium-functionalized device is catalytically active in vivo.
Concurrently, a strong ﬂuorescent signal was also observed from
the gastrointestinal system33,34 in ﬁsh incubated with pro-
ﬂuorophore 3 regardless of the presence or absence of Pd0-resin
(Fig. 4c, pointed with white arrow heads, and Supplementary
Fig. 10), suggesting that the N-propargyloxycarbonyl (N-Poc)
group is biochemically cleaved by digestive enzymes. Although
compound 3 exhibited high sensitivity to palladium catalysis, it
also displayed low chemical stability in the digestive system,
indicating that N-Poc masked prodrugs could not be used via oral
administration in a bioorthogonal strategy.
Discussion
For more than a decade1–3, the concept of bioorthogonal
chemistry (understood as performing chemical reactions by
artiﬁcial biologically inert means under biocompatible
conditions) has inspired the search for novel biocompatible
organic reactions and found a niche application as a labelling
strategy to study biomolecules in their native state1–5,35. Indeed,
bioorthogonal reactions have become particularly useful to study
biological small molecules and macromolecules that cannot be
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4277
4 NATURE COMMUNICATIONS | 5:3277 |DOI: 10.1038/ncomms4277 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
monitored by genetically encoded reporters or antibodies (for
example, lipids, glycans, and so on) both in cells and in vivo4,35.
Although metal-free bioorthogonal reactions are considered
optimal for living systems because of their biocompatibility,
signiﬁcant progress has been made in recent years in the
development of cell-tolerated BOOM reactions8–14,35,36,
opening up new avenues for the exploitation of the bio-
orthogonal paradigm. However, the potential of such selective
processes in medicine is yet to be determined. Within an inclusive
notion of bioorthogonality5, the clinical potential of bio-
orthogonal processes has only been explored to date with
the photoinduced generation of cytotoxic reactive oxygen
species through the use of a harmless visible light source and a
non-toxic photosensitizer, which has become a valuable
therapeutic option for local treatment of disease (so-called
photodynamic therapy37).
In this line of reasoning, here we report a novel palladium-
mediated N-dealkylation that takes place under biocompatible
conditions and its application beyond the current scope of
BOOM reactions: a highly efﬁcient masking method that achieves
complete elimination of 5FU cytotoxic activity, while enabling the
bioorthogonal restoration of the drug’s pharmacological proper-
ties by heterogeneous palladium chemistry in cell culture.
In accordance with 5FU mode of action (Fig. 1), modiﬁcation
of its N1 position with each of the three alkyl groups investigated
(allyl, propargyl and benzyl; Fig. 2c) generates harmless prodrugs
(Supplementary Fig. 7a,b), which demonstrates the low suscept-
ibility of alkyl groups to cleavage by hydrolytic enzymes.
However, under biocompatible conditions, only the propargyl
group displays high sensitivity to Pd0-resins, thereby allowing the
palladium-catalysed N-dealkylation of Pro-5FU at 37C in PBS
(isotonic, aqueous solution buffered at pH¼ 7.4) within 24 h.
Although the high stability of the benzyl moiety was anticipated
because of the lack of an additional hydrogen source20, the drastic
difference in Pd0 sensitivity between Pro-5FU and All-5FU
suggests that electronic and/or conformational aspects are critical
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for efﬁcient metal coordination and cleavage (Supplementary
Fig. 2a). To brieﬂy examine the potential scope of the N-
depropargylation process, N-propargyl-2-pyridone (1a) and N-
propargyl-4-pyridone (1b) were synthesized and treated under
the same conditions as Pro-5FU (Supplementary Fig. 3d).
Dealkylated products were obtained within 24 h, indicating that
this environmentally friendly methodology could be translated to
other heterocyclic systems with lactam/lactim tautomery. Because
of its implications for the bioorthogonal use of this novel masking/
activation strategy, it is important to highlight that the palladium-
mediated oxidative cleavage of the N-propargyl group in aqueous
media results in the formation of non-toxic 1-hydroxyacetone26
(Supplementary Fig. 2b). The generation of this natural
compound29 would minimize any local off-target effects caused
by side products originated from the activation process itself.
Our results show that, at the concentrations tested, neither the
prodrug nor the palladium source exhibits antiproliferative
activity in any of the cancer cell lines (Fig. 3), thus validating
the in vitro bioorthogonality of the materials. In contrast, the
combined use of Pro-5FU and Pd0-resins led to a toxigenic effect
comparable to 5FU antiproliferative activity, which demonstrates
the in situ generation of 5FU. A variance in cytotoxicity was
observed at several doses (Fig. 3a,b), which may be due to the
time lag required for the BOOM reaction to take place and
produce cytotoxic levels of drug. This difference was not
signiﬁcant in BxPC-3 cells at Pro-5FU doses higher than 1 mM
(Fig. 3b), indicating that cytotoxic levels for this sensitive cell line
are rapidly generated.
Monitoring of HCT116 cell proliferation by time-lapse imaging
allowed visualizing the slower antiproliferative effect led by the
Pro-5FU/Pd0-resins combination (BOOM conversion assay) in
comparison to unmodiﬁed 5FU (Fig. 3c). This result is in
accordance with the time delay required to generate cytotoxic
levels of drug for this cell line. Owing to the higher sensitivity of
BxPC-3 cells to 5FU, both drug and the prodrug/catalyst
combination experiments showed comparable bell-shaped popu-
lation curves (Fig. 3d). In agreement with these observations, our
immunoassay studies shows an analogous cell death induction
mechanism between 5FU and the prodrug/catalyst system,
corroborating that the cytotoxic activity generated by the
prodrug/Pd0-resin combination is due to the BOOM synthesis
of 5FU in cell culture.
In conclusion, the development of a biochemically resistant
palladium-labile 5FU precursor and an extracellular Pd0-
functionalized device enabled the in vitro bioorthogonal trans-
formation of a biologically inert substance into a cytotoxic agent.
Although this novel prodrug strategy is yet to be tested in disease
models in vivo, the robustness of the masking strategy, the
biocompatibility of the dealkylation conditions and the innocuous
reaction byproduct (natural product 1-hydroxyacetone26,29)
underline the therapeutic potential of this novel masking/
activation approach. Finally, the biocompatibility and local
catalytic activity exhibited by the Pd0-resin implanted within
the zebraﬁsh yolk supports the development of more compre-
hensive in vivo pharmacodynamics, pharmacokinetics and
toxicity investigations in order to study the applicability and
potential beneﬁts of implementing a bioorthogonally activated
prodrug approach.
Methods
General methods. Chemicals and solvents were purchased from Fisher Scientiﬁc,
Sigma-Aldrich or VWR International Ltd. Nuclear magnetic resonance (NMR)
spectra were recorded at ambient temperature on a 500-MHz Bruker Avance III
spectrometer (Bruker). Chemical shifts are reported in parts per million (p.p.m.)
relative to the solvent peak. Rf values were determined on Merck TLC Silica
gel 60 F254 plates (Merck) under a 254-nm ultraviolet source. Puriﬁcation of
compounds was carried out via manual ﬂash column chromatography using
commercially available silica gel (220–440 mesh, Sigma-Aldrich). Cell lines were
grown in culture media supplemented with serum (10% fetal bovine serum) and
L-glutamine (2mM) and incubated in a Heracell 240i tissue culture incubator at
37 C and 5% CO2. Human colorectal carcinoma HCT116 cells (a kind gift from
Dr Van Schaeybroeck) were cultured in Dulbecco’s Modiﬁed Eagle Media
(DMEM). Human pancreas adenocarcinoma BxPC-3 cells (a kind gift from
Dr Mark Duxbury) were cultured in Roswell Park Memorial Institute media.
Human hepatocyte carcinoma HepG2 cells were obtained from Sigma-Aldrich
and cultured in DMEM.
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Figure 4 | Biocompatibility and catalytic activity of Pd0-resins in zebraﬁsh embryos. (a) Images of a zebraﬁsh embryo containing a Pd0-resin (red arrow)
in the yolk sac at different stages of development. Twenty-four hours after fertilization (24 h.p.f.), a Pd0-resin was implanted in each embryo yolk (n¼ 5),
incubated at 28 C and ﬁsh monitored for 4 days. Fish were imaged at 24 h.p.f., 3 days post fertilization (3 d.p.f.) and 4 d.p.f. (b) Palladium-mediated
conversion of non-ﬂuorescent lipophilic compound 3 into highly ﬂuorescent hydrophilic rhodamine 110. (c) In vivo carbamate cleavage of compound 3. One
day after implantation, zebraﬁsh embryos (n¼ 5) containing a Pd0-resin (black colour) or a naked resin (white colour) in the yolk sac were incubated
with compound 3 (5mM) for 24 h at 31 C. Subsequently, ﬁsh were imaged using confocal microscopy (Ex/Em: 488/521 nm). Pd0-resins and naked
resin are indicated with red arrows. Fluorescently labelled gastrointestinal tract is indicated with a white arrow head.
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Synthesis and characterization of Pd0-resins. NovaSyn TG amino resin HL
(1,000mg, 0.39mmol NH2 per g) and palladium acetate (263mg, 1.17mmol) were
added into a 25ml Biotage microwave vial (Biotage) with toluene (10ml) and
heated to 80 C under stirring for 10min. The mixture was then stirred at room
temperature for 2 h and the resins subsequently ﬁltered and washed with
dichloromethane (5 20ml) and methanol (5 20ml). Resins were dispersed in
10% hydrazine monohydrate in methanol (10ml) and stirred at room temperature
for 25min. The resins were then ﬁltered and washed with methanol (5 20ml)
and dichloromethane (5 20ml). Resins were added to a solution of Fmoc-
Glu(OH)-OH (216mg, 0.59mmol), Oxyma (166mg, 1.17mmol), N,N0-diisopro-
pylcarbodiimide (DIC) (148mg, 1.17mmol) and DCM/DMF (2:1, 9ml) and stirred
for 2 h at room temperature. The resins were ﬁltered and washed with dichlor-
omethane (5 20ml), methanol (5 20ml) and H2O (5 20ml) and dried in an
oven at 40 C for 3 days. Complete coupling was veriﬁed by the ninhydrin test after
the last methanol wash. Scanning electron microscope/transmission electron
microscope images and Pd0 quantiﬁcation (by inductively coupled plasma-optical
emission spectrometry) were carried out as previously described8. Resins were
characterized using X-ray difractometry (Bruker D2 PHASER with LYNXEYE
detector (Bruker), Cu radiation source at 30 kV, 10mA and a Ni ﬁltre) before and
after Pd0-functionalization. Without any extra preparation or post-processing,
samples were mounted on a 1 inch diameter standard holder. The phase
constituents were identiﬁed as per Supplementary Fig. 1c.
Synthesis and characterization of 5FU prodrugs. 5FU (200mg, 1.54mmol) and
1,8-diazabicyclo[5.4.0]undec-7-ene (269 ml, 1.80mmol) were dissolved in dry DMF
(2ml) under N2 atmosphere and cooled to 4 C. Either allyl, propargyl or benzyl
bromide (1.54mmol) were dissolved in dry DMF (0.5ml). The solution was added
dropwise to the mixture and the resulting mixture stirred at room temperature
overnight. Solvents were then removed under reduced pressure and the crude
puriﬁed via ﬂash chromatography (3% MeOH in DCM).
1-Allyl-5FU (All-5FU): colourless solid, 80mg (31% yield); Rf¼ 0.5 (6% MeOH
in DCM); 1H NMR (500MHz, dimethylsulphoxide (DMSO)-d6) d¼ 11.80 (br s,
1H, NH), 8.01 (d, J(HH)¼ 6.7Hz, 1H, ArH), 5.88 (ddt, J(HH)¼ 17.0,
J(HH)¼ 10.5Hz, J(HH)¼ 5.5Hz, 1H, N–CH2–CH), 5.19 (m, 2H, CH2–CH¼
CH2), 4.24 (d, J(HH)¼ 5.3Hz, 2H, N–CH2–CH); 13C NMR (126MHz, DMSO)
d¼ 157.45 (d, J(CF)¼ 25.5Hz, C), 149.46 (C), 139.68 (d, J(CF)¼ 229.5Hz, C),
132.63 (CH), 129.79 (d, J(CF)¼ 33.0Hz, CH), 117.64 (CH2), 49.34 (CH2); high-
resolution mass spectrometry (HRMS) fast atom bombardment (FAB) (m/z):
[M]þ calcd for C7H7O2N2F, 170.0486; found, 170.0489.
Pro-5FU: colourless solid, 104mg (40% yield); Rf¼ 0.35 (6% MeOH in DCM);
1H NMR (500MHz, DMSO-d6) d¼ 11.91 (br s, 1H, NH), 8.13 (d, J(HH)¼ 5.0Hz,
1H, ArH), 4.46 (d, J(HH)¼ 2.5Hz, 2H, N–CH2–C), 3.44 (t, J(HH)¼ 2.5Hz, 1H,
CCH); 13C NMR (126MHz, DMSO) d¼ 157.35 (d, J(CF)¼ 26.0Hz, C), 149.11
(C), 139.80 (d, J(CF)¼ 230.5Hz, C), 128.95 (d, J(CF)¼ 34.0Hz, CH), 78.40 (C),
76.15 (CH), 37.00 (CH2); HRMS (FAB) (m/z): [M]þ calcd for C7H5O2N2F,
168.0332; found, 168.0330.
1-Benzyl-5FU (Bn-5FU): pale yellow solid, 133mg (38% yield); Rf¼ 0.44 (6%
MeOH in DCM); 1H NMR (500MHz, DMSO-d6) d¼ 11.86 (br s, 1H, NH), 8.22
(d, J(HH)¼ 6.7Hz, 1H, ArH), 7.39–7.28 (m, 5H, ArH), 4.83 (s, 2H, N–CH2–Ph);
13C NMR (126MHz, DMSO-d6) d¼ 157.42 (d, J(CF)¼ 25.5Hz, C), 149.68 (C),
139.62 (d, J(CF)¼ 228.0Hz, C), 136.52 (C), 130.08 (d, J(CF)¼ 33.5Hz, CH),
128.67 (CH), 127.75 (CH), 127.49 (CH), 50.63 (CH2); HRMS (FAB) (m/z): [M]þ
calcd for C11H9O2N2F, 220.0643; found, 220.0643.
Synthesis and characterization of probe 3. Rhodamine 110 chloride (250mg,
0.68mmol) was dissolved in dry DMF (4ml) under nitrogen atmosphere. Sepa-
rately, propargyl chloroformate (273 ml, 2.80mmol) and triethylamine (488 ml,
3.50mmol) were added dropwise to the mixture. The reaction mixture was stirred
at room temperature for 48 h, solvents removed in vacuo and the resulting crude
re-suspended in 25% isopropanol in DCM (20ml) and washed with H2O. The
aqueous layer was then washed ﬁve times with 25% isopropanol in DCM (20ml).
The combined organic layers were dried over anhydrous MgSO4, the solids ﬁltered
off and concentrated in vacuo. Crude was puriﬁed via ﬂash chromatography
(hexane/ethyl acetate 2:1) and yielded bis-N,N0-propargyloxycarbonyl-rhodamine
110 (3) as a white solid (67mg, 20%). Rf¼ 0.13 (hexane/ethyl acetate 2:1); 1H
NMR (500MHz, CD3OD) d¼ 8.02 (d, J(HH)¼ 7.5Hz, 1H, ArH), 7.77 (td,
J(HH)¼ 7.5Hz, 1.1, 1H, ArH), 7.71 (td, J(HH)¼ 7.5Hz, 0.9, 1H, ArH), 7.61 (d,
J(HH)¼ 2.0Hz, 2H, ArH), 7.21 (d, J(HH)¼ 7.6, 1H, ArH), 7.08 (dd, J(HH)¼ 8.5
Hz, 2.2, 2H, ArH), 6.68 (d, J(HH)¼ 8.5Hz, 2H, ArH), 4.78 (d, J(HH)¼ 2.4Hz, 4H,
CH2–CCH), 2.94 (t, J(HH)¼ 2.4Hz, 2H, CCH); 13C NMR (126MHz, MeOD)
d¼ 171.35 (C), 154.59 (C), 154.43 (C), 153.18 (C), 142.65 (C), 136.74 (CH), 131.27
(CH), 129.47 (CH), 127.76 (C), 125.89 (CH), 125.19 (CH), 115.60 (CH), 114.42
(C), 107.04 (CH), 84.48 (C), 79.08 (C), 76.22 (C), 53.40 (CH2); mass spectrometry
(electrospray ionization) (m/z): 495.2 [MþH]þ .
Pd0-mediated prodrug dealkylation in biocompatible environ. All-5FU, Pro-
5FU and Bn-5FU (100 mM) were dissolved in PBS (1ml) with 1mg of Pd0-resins
and shaken at 1,400 r.p.m. and 37 C in a Thermomixer. Reaction crudes were
monitored at 0, 6, 24 and 48 h by analytical HPLC (Agilent) using the ultraviolet
detector at 280 nm to avoid the detection of PBS salts. Eluent A: water and formic
acid (0.1%); eluent B: acetonitrile, formic acid (0.1%); A/B¼ 95:5 to 5:95 in 3min,
isocratic 1min, 5:95 to 95:5 in 1min, isocratic 1min. Catalytic conversion assay:
Pro-5FU in 0.1% (v/v) DMSO was dissolved in PBS (1ml) with Pd0-resins
(1mgml 1, [Pd0]B266mM) to reach a ﬁnal Pro-5FU concentration 300 mM and
incubated for 24, 48, 72 h at 37 C. Pro-5FU presence was monitored by HPLC. For
the heterogeneous catalysis assay, Pd0-resins (2mg) were dispersed into a PBS
solution (2ml) and incubated for 24 h at 37 C. The mixture was ﬁltrated using a
Millipore microﬁltre (0.22 mm, Millipore) and, subsequently, Pro-5FU added to the
mixture (ﬁnal concentration¼ 100mM). The reaction mixture was incubated for
additional 24 h and analysed by HPLC (ultraviolet detector at 280 nm).
Cell viability studies of 5FU versus Pro-5FU. Cells were seeded in a 96-well plate
format at the appropriate cell concentration (3,000 cells per well for HCT116 and
BxPC-3 cells, and 4,000 cells per well for HepG2 cells) and incubated for 48 h
before treatment. Each well was then replaced with fresh media containing 5FU
(0.01 mM to 1mM) with DMSO (0.1% v/v); or Pro-5FU (0.01 mM to 1mM) with
DMSO (0.1% v/v) and incubated for 5 days. Untreated cells were incubated with
DMSO (0.1% v/v). PrestoBlue cell viability reagent (10% v/v) was added to each
well and the plate incubated for 45min. Fluorescence emission was detected using a
PerkinElmer EnVision 2101 multilabel reader (Perkin Elmer; excitation ﬁltre at
540 nm and emissions ﬁltre at 590 nm). All conditions were normalized
to the untreated cells (100%) and curves ﬁtted using GraphPad Prism using a
sigmoidal variable slope curve.
Pd0-mediated dealkylation of Pro-5FU in cell culture. HCT116 and BxPC-3
cells were seeded in a 96-well plate format with a density of 3,000 cells per well
and incubated for 48 h before treatment. Each well was then replaced with fresh
media containing: Pd0-resins (0.67 or 1mgml 1 for BxPC-3 or HCT116,
respectively) with DMSO (0.1% v/v); Pro-5FU (0.01–100 mM) with DMSO
(0.1%, v/v); 5FU (0.01 mM to 1mM) with DMSO (0.1%, v/v) or combination
of Pd0-resinþPro-5FU (0.01–100mM) with DMSO (0.1%, v/v). Untreated cells
were incubated with DMSO (0.1% v/v). For the cell viability assay, cells were
incubated with drugs for 5 days. PrestoBlue cell viability reagent (10% v/v) was
added to each well and the plate incubated for 45min. Fluorescence emission
was detected and results normalized as described above. For the time lapse imaging
study, cell growth studies were carried out at a single dose of 5FU or Pro-5FU
(100 mM for HCT116 and 30mM for BxPC-3). Each well was imaged every 2 h
over 5 days under standard incubation conditions using an IncuCyte ZOOM
microscope (placed inside the incubator). Imaged-based analysis of cell
conﬂuence and Supplementary Movies 1 and 2 were carried out using the
IncuCyte software.
Reverse phase protein array analysis. Cells were plated in a 6-well plate at a
density of 480,000 cells per well and incubated for 48 h. Before adding the prodrug
to the HCT116 cells, Pro-5FU (100 mM) and Pd0-resins (1mgml 1) were incu-
bated in media at 37 C for 24 h to overcome the time delay required to convert
Pro-5FU into 5FU, which was seen to have a relevant effect in this cell type. This
pre-incubation procedure was not carried out for the study with BxPC-3 cells
(30 mM). Pd0 resin/Pro-5FU combination and the controls (as before, untreated
cells; Pd0-resins; Pro-5FU and 5FU) were incubated with each cell line for 6 and
24 h. Afterwards, the cells were washed with PBS (2 3ml) and lysed with Zep-
tosens CLB1 lysis buffer (90 ml, Zeptosens). Samples were analysed by Zeptosens
RPPA (Zeptosens) as previously described31 using the following speciﬁc
conditions. Tumour cell lysates were normalized to a uniform protein
concentration with spotting buffer CSBL1 (Zeptosens-Bayer) before preparing a
ﬁnal fourfold concentration series of 0.2, 0.15, 0.1 and 0.05mgml 1. The diluted
concentration series of each sample was printed onto Zeptosens protein microarray
chips (ZeptoChip, Zeptosens-Bayer) under environmentally controlled conditions
(constant 50% humidity and 14 C temperature) using a non-contact printer
(Nanoplotter 2.1e, GeSiM). A single 400 Pico litre droplet of each lysate
concentration was deposited onto the Zeptosens chip (thus representing four spots
per each biological replicate). A reference grid of Alexa Fluor-647 conjugate BSA
consisting of 4 column 22 rows was spotted onto each sub-array. Each sample
concentration series were spotted in between reference columns. After array
printing, the arrays were blocked with an aerosol of BSA solution using a custom
designed nebulizer device (ZeptoFOG, Zeptosen-Bayer) for 1 h. The protein array
chips were subsequently washed in double-distilled H2O and dried before
performing a dual antibody immunoassay comprising of a 24-h incubation of
primary antibody (the library of primary antibodies used is in Supplementary
Table 1 and were purchased from Cell Signaling Technologies) followed by 2.5 h
incubation with secondary Alexa Fluor-conjugated antibody detection reagent
(anti-rabbit A647 Fab; Invitrogen). Following secondary antibody incubation and a
ﬁnal wash step in BSA solution, the immunostained arrays were imaged using the
ZeptoREADER instrument (Zeptosens-Bayer). For each sub-array, ﬁve separate
images were acquired using different exposure times ranging from 0.5 to 10 s.
Microarray images representing the longest exposure without saturation of
ﬂuorescent signal detection were automatically selected for analysis using the
ZeptoView 3.1 software (Zeptosens-Bayer). A weighted linear ﬁt through the
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fourfold concentration series was used to calculate relative ﬂuorescence intensity
(RFI) value for each sample replicate. Local normalization of sample signal to the
reference BSA grid was used to compensate for any intra- or inter-array/chip
variation. Local normalized RFI values were used for all subsequent analysis.
Abundance levels of total p53 protein, phosphorylated p53 (Serine 15) and
phosphorylated Akt (Ser 473) were plotted as RFI data calculated by the ZeptoView
3.1 software.
Western blot analysis. Cell lysates for HCT116 and BxPC-3 cells were prepared
as described above for Zeptosens analysis. Protein samples (35 mg) and SeeBlue
Plus2 Pre-Stained Standard (7.5 mg) were separated by SDS-PAGE (Bio-Rad,
4–15% gels) and transferred to PVDF membranes (GE). Western blotting was
performed using rabbit monoclonal antibodies against human p53 and Phospho-
p53 (Ser 15) (1:1,000 for each one, Cell Signaling Technologies, cat. no. 9282 and
9284, respectively) at 4 C overnight. This was followed by 1 h incubation at room
temperature with secondary horseradish peroxidase (HRP)-linked antibody
(1:10,000, anti-rabbit IgG, Sigma). The loading control, actin, was detected using a
mouse monoclonal antibody (1:40,000, Calbiochem, cat. no. CP01) followed by a
secondary HRP-linked antibody treatment (1:40,000, anti-mouse IgM, Calbio-
chem). HRP was detected by addition of POD ECL (Roche) and bands visualized
using a ChemiDoc MP Imager (Bio-Rad).
Zebraﬁsh studies. For the biocompatability assay, wild-type zebraﬁsh embryos
were collected from AB-TPL breeding pairs and reared at 28 C in E3 embryo
medium. Twenty-four hours post fertilization, embryos were treated with tricaine
(anesthetic) and pierced in the yolk with a ﬁne needle. Either a naked resin or a
Pd0-resin was then rapidly inserted into the yolk opening to minimize loss of yolk.
Embryos that lost signiﬁcant yolk in the procedure were removed from the
experiment. Embryos were then gently transferred to fresh E3 medium (n¼ 5),
returned to 28 C and monitored over 3 days by microscopy. For the catalytic
activity assay, either a naked resin or a Pd0-resin was implanted in 24 h.p.f. zeb-
raﬁsh embryos (n¼ 5) following the above procedure and gently transferred to
fresh E3 medium. Embryos were incubated for 24 h at 28 C to ensure the yolk
wound was closed. Embryos that lost signiﬁcant yolk in the procedure were
removed from the experiment. Compound 3 was added to the embryo medium
(ﬁnal concentration 5 mM) and ﬁsh incubated for additional 24 h at 31 C to
increment the probe activation rate. Fish were imaged using ﬂuorescent micro-
scopy (Olympus Scan-R, Olympus). It is important to note that the zebraﬁsh
embryos looked older than developmental 3 d.p.f., probably due to the increased
incubation temperature (31C). Experiments were repeated three times. Zebraﬁsh
husbandry and experiments were performed under Home Ofﬁce License in com-
pliance with the Animals (Scientiﬁc Procedures) Act 1986, and approved by the
University of Edinburgh Ethics Committee.
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